Search in the Abstract Database

Search Abstracts 2012

* = Presenting author

P264. Cytokine ratios in Crohn's disease clinical remission before and after the intake of a probiotic


P. Nikolov1, M. Baleva2

1St. Ivan Rilsky University Hospital, Sofia, Sofia, Bulgaria; 2University Hospital Alexandrovska, Department of Clinical Immunology, Sofia, Bulgaria



Background: There are only several studies discussing changes in a cytokine ratio in Crohn's disease (CD) and they are all focused on the ratio between the anti-inflammatory IL‑1 receptor antagonist and the pro-inflammatory IL‑1-beta (IL‑1ra/IL‑1-beta ratio). We could not find any reports discussing changes in cytokine ratios modified by probiotics in CD clinical remission. The aim of our study was to investigate the changes and the correlations between the ratios of the anti-inflammatory IL‑10, IL‑13 and the pro-inflammatory IL‑8, IL‑12 and IFN-gamma in CD clinical remission before and after the intake of a probiotic.

Methods: The study included 15 patients with CD (3 men, 12 women, mean age 43.1±11, 22–59 years) in clinical remission (CDAI <150) and 15 controls (6 men, 9 women, mean age 37.6±13.6, 25–60 years). All subjects received daily 3.75 billion colony forming units Lactobacillus bulgaricus ATCC 21815 for 28 days. The serum levels of cytokines were measured by ELISA on day 0 and day 28.

Results: Before the probiotic intake we found no significant difference between the cytokine ratios and their correlations in CD and controls (p > 0.05). However after the probiotic intake in CD we found a positive correlation between the ratios IL‑10/IL‑12 and IL‑13/IL‑8 (R = 0.571; p = 0.028) and it was different than the correlations found in controls – IL‑10/IL‑12 and IL‑13/IFN-gamma (R = 0.525; p = 0.044); IL‑13/IL‑12 and IL‑10/IL‑8 (R = 0.575; p = 0.025).

Conclusions: Cytokine ratios are a novel marker of immune reactivity in CD. Our results raise the question whether the differences in cytokine ratios after the probiotic intake may be a result of altered immune reactivity in CD clinical remission.